

Congress of the United States

House of Representatives

COMMITTEE ON OVERSIGHT AND GOVERNMENT REFORM

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225-5074
MINORITY (202) 225-6061
<https://oversight.house.gov>

MEMORANDUM

September 10, 2026

To: Members, Subcommittee on Health Care and Financial Services

From: Committee Staff

Re: Hearing titled “Unequal Treatment: Addressing the Drivers of Unaffordability for Oral Chemotherapy”

On Tuesday, September 15, 2026, at 10 a.m. ET in 2154 Rayburn House Office Building, the Subcommittee on Health Care and Financial Services will host a hearing titled “Unequal Treatment: Addressing the Drivers of Unaffordability for Oral Chemotherapy.”

I. BACKGROUND:

Cancer patients are increasingly prescribed chemotherapy in pill form, but insurers and pharmacy benefit managers have not updated their coverage rules accordingly. Rather than covering intravenous (IV) and oral chemotherapy treatment equally, patients regularly pay significantly higher out-of-pocket costs for oral chemotherapy than for IV treatment.

II. HEARING PURPOSE:

This hearing will examine the healthcare industry practices that result in higher patient costs for oral chemotherapy than IV treatment and explore the steps Congress can take to resolve this issue.

III. WITNESSES:

Mr. Ted Okon

Executive Director

Community Oncology Alliance

Dr. Sheetal M. Kircher

Clinical Practice Director and Medical Director

Survivorship Institute, Robert H. Lurie Comprehensive Cancer Center

Northwestern University